The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in high-risk myelodysplastic syndromes (MDS) cases with unfavorable prognosis. However, little is known about the molecular mechanisms underlying this therapy, and molecular markers useful to monitor the disease and the effect of the treatment are needed. Phosphoinositide-phospholipase C (PI-PLC) Β1 is involved in both genetic and epigenetic mechanisms of MDS progression to acute myeloid leukemia. Indeed, AZA as a single agent was able to induce PI-PLCΒ1 expression, therefore providing a promising new tool in the evaluation of response to demethylating therapies. In this study, we assessed the efficacy of the combination of AZA and VPA on inducing PI-PLCΒ1 expression in high-risk MDS patients. Furthermore, we observed an increase in Cyclin D3 expression, a downstream target of PI-PLCΒ1 signaling, therefore suggesting a potential combined activity of AZA and VPA in high-risk MDS in activating PI-PLCΒ1 signaling, thus affecting cell proliferation and differentiation. Taken together, our findings might open up new lines of investigations aiming at evaluating the role of the activation of PI-PLCΒ1 signaling in the epigenetic therapy, which may also lead to the identification of innovative targets for the epigenetic therapy of high-risk MDS.

Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes / Follo, MATILDE YUNG; Finelli, Carlo; Mongiorgi, Sara; Clissa, C; Chiarini, Francesca; Ramazzotti, Giulia; Paolini, Stefania; Martinelli, Giovanni; Martelli, ALBERTO MARIA; Cocco, LUCIO ILDEBRANDO. - In: LEUKEMIA. - ISSN 0887-6924. - 25:(2011), pp. 271-280. [10.1038/leu.2010.266]

Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes

CHIARINI, FRANCESCA;COCCO, LUCIO ILDEBRANDO
2011-01-01

Abstract

The association between azacitidine (AZA) and valproic acid (VPA) has shown high response rates in high-risk myelodysplastic syndromes (MDS) cases with unfavorable prognosis. However, little is known about the molecular mechanisms underlying this therapy, and molecular markers useful to monitor the disease and the effect of the treatment are needed. Phosphoinositide-phospholipase C (PI-PLC) Β1 is involved in both genetic and epigenetic mechanisms of MDS progression to acute myeloid leukemia. Indeed, AZA as a single agent was able to induce PI-PLCΒ1 expression, therefore providing a promising new tool in the evaluation of response to demethylating therapies. In this study, we assessed the efficacy of the combination of AZA and VPA on inducing PI-PLCΒ1 expression in high-risk MDS patients. Furthermore, we observed an increase in Cyclin D3 expression, a downstream target of PI-PLCΒ1 signaling, therefore suggesting a potential combined activity of AZA and VPA in high-risk MDS in activating PI-PLCΒ1 signaling, thus affecting cell proliferation and differentiation. Taken together, our findings might open up new lines of investigations aiming at evaluating the role of the activation of PI-PLCΒ1 signaling in the epigenetic therapy, which may also lead to the identification of innovative targets for the epigenetic therapy of high-risk MDS.
25
271
280
Synergistic induction of PI-PLCbeta1 signaling by azacitidine and valproic acid in high-risk myelodysplastic syndromes / Follo, MATILDE YUNG; Finelli, Carlo; Mongiorgi, Sara; Clissa, C; Chiarini, Francesca; Ramazzotti, Giulia; Paolini, Stefania; Martinelli, Giovanni; Martelli, ALBERTO MARIA; Cocco, LUCIO ILDEBRANDO. - In: LEUKEMIA. - ISSN 0887-6924. - 25:(2011), pp. 271-280. [10.1038/leu.2010.266]
Follo, MATILDE YUNG; Finelli, Carlo; Mongiorgi, Sara; Clissa, C; Chiarini, Francesca; Ramazzotti, Giulia; Paolini, Stefania; Martinelli, Giovanni; Martelli, ALBERTO MARIA; Cocco, LUCIO ILDEBRANDO
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1288368
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 30
social impact